研究方向：
聚焦疾病特异性生物标志物（癌症：FAP、PSMA、STING等；细菌感染；无菌炎症），开发新型核素探针，用于疾病的诊疗研究；
多策略调控核素探针体内药代动力学性质，推动核素药物临床转化。
项目经历：主持第73批博士后面上项目（2023M742916），2024年入选国家博士后资助研究人员计划（GZC 20240891）
教育工作经历：
2025.08-至今威廉体育威廉希尔体育副教授
2023.7-2025.07厦门大学公共卫生公司影像医学与核医学博士后
（导师：郭志德副教授）
2017.09-2023.06厦门大学公共卫生公司生物化学与分子生物学理学博士
（导师：张现忠教授，郭志德副教授）
2013.09-2017.06福建师范大学化学与化工公司应用化学学士
（导师：卢玉栋教授）
个人简介：
本人参与多项国家自然科学基金等科研项目，作为工艺开发及质控组负责人参与多项放射性新药的IND申报并支持获得多项CDE及FDA新药临床试验批件。曾获第八届全国同位素制备及应用研讨会“青年优秀论文奖”、第五届分子影像学厦门论坛“青年学者奖”，并在第二届全国博士后创新创业大赛福建省选拔赛中荣获前三名。近5年共发表SCI论文31篇，其中以第一作者/通讯（含共同）在核医学领域顶级期刊共发表15篇，其中top期刊12篇：J. Nucl. Med.（3篇）、Eur. J. Nucl. Med. Mol. Imaging.（2篇），J. Med. Chem.（5篇），J. Control. Release. (2篇)，获得7项专利授权。H-index：12。
联系邮箱：fangjy8228@fjmu.edu.cn
ResearchGate主页：https://www.researchgate.net/profile/Jianyang-Fang
代表性论文（#：共同作者；*：共同通讯）
[1]Jianyang Fang#, Lixia Feng#, Lingxin Meng#, et al., A novel 18F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice, European Journal of Nuclear Medicine and Molecular Imaging, 2022, 50(1): 27-37.
[2]Jianyang Fang#, Xiaobo Wang#, Lingxin Meng, et al., Preclinical Evaluation of 131I/18F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging, ACS Pharmacology & Translational Science. 2024, 7(6): 1783-1794
[3]Jianyang Fang#, Jingru Zhang#, Lingxin Meng, et al.,18F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor, Molecular Pharmaceutics. 2024, 21(4): 1942-1951.
[4]Lumei Huang#, Jianyang Fang#, Shouqiang Hong, et al., MicroPET imaging of bacterial infection with nitroreductase-specific responsive 18F-labelled nitrogen mustard analogues, European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49(8): 2645-2654.
[5]Lingxin Meng#, Jianyang Fang#, Liang Zhao#, et al., Rational Design and Pharmacomodulation of Protein-Binding Theranostic Radioligands for Targeting the Fibroblast Activation Protein, Journal of Medicinal Chemistry, 2022, 65(12): 8245-8257.
[6]Lingxin Meng#, Jianyang Fang#, Jingru Zhang, et al., Rational Design and Comparison of Novel 99mTc-Labeled FAPI Dimers for Visualization of Multiple Tumor Types, Journal of Medicinal Chemistry.2024,
[7]Liang Zhao#, Yizhen Pang#, Jianyang Fang#, et al., Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma, Journal of Nuclear Medicine, 2024, 65(3): 394-401.
[8]Yizhen Pang#, Liang Zhao#, Jianyang Fang#, et al., Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy. Journal of Nuclear Medicine, 2023, 64(9): 1449-1455.
[9]Liang Zhao#, Bo Niu#, Jianyang Fang#, et al., Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of 68Ga-labeled FAPI dimer, Journal of Nuclear Medicine, 2022, 63(6): 862-868.
[10]Lingxin Meng#, Jianyang Fang#, Xiaoru Lin#, et al. Developments of radioligands with an albumin-binding moiety of 4-(P-Iodophenyl) butyric acid[J]. Journal of Controlled Release, 2025: 113757.
[11]……, Jianyang Fang*, Xianzhong Zhang*, and Zhide Guo*, Rational Design and Pharmacomodulation of 18F-Labeled Biotin/FAPI-Conjugated Heterodimers, Journal of Medicinal Chemistry.2024, 67(10): 8361-8371.
[12]……, Jianyang Fang*, Weibing Miao*, and Zhide Guo*, Modification of Asp–Peptide Adapters: Giving the FAP-Targeted Radioligand a “Squirrel Tail”, Journal of Medicinal Chemistry, 2025, 2025(6):68
[13]……, Jianyang Fang*, Xianzhong Zhang*, and Zhide Guo*, FAP-targeted delivery of radioiodinated probes: A progressive albumin-driven strategy for tumor theranostics[J]. Journal of Controlled Release, 2025: 113678.
